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Background: Mycophenolate mofetil (MMF) is frequently
combined with cyclosporine-A (CSA) as immunosuppression
in CBT. Drug monitoring of MPA, the active MMF metabolite,
is advisable based on variable MMF pharmacokinetics and
the association of low unbound MPA AUCs with increased
aGVHD. This is highly relevant in CBT as aGVHD is a leading
cause of mortality. However, a limited pharmacokinetic
parameter such as MPA troughs is ideal. Additionally, the
toxicity associatedwithMPA troughs is not established and is
of concern in CBT due to the theoretical risk of myelosup-
pression from high levels.
Methods: We evaluated the association between serial
(weeks 1-6) total MPA trough levels and outcomes in double-
unit CBT recipients transplanted 8/2009-11/2012. Intravenous
CSA/MMF commenced on day -3. Trough levels were dichot-
omized into <2 mcg/mL and 2 mcg/mL for the toxicity
analysis (engraftment, gastro-intestinal toxicity as measuredby TPN duration and CMV infection) at each time point. For
the efﬁcacy (aGVHD prevention) analysis, meanweek 1 and 2
trough levels were split at <0.5 vs 0.5 mcg/mL.
Results: Eighty-three patients (median age 44 years, range
1-71) had weekly MPA levels for 6 weeks after CBT. Sixty-
nine (83%) received myeloablative (MA) conditioning and 45
(54%) were CMV seropositive. Median trough levels ranged
0.6-1.3 mcg/mL. Trough levels increased over time (p¼0.03).
Myeloablative (MA) had lower MPA troughs than non-mye-
loablative recipients (p¼0.02). Younger age (0-15 years old)
was associated with lower trough levels (p¼0.002). By
time-dependent Cox regression analysis, there was no
association between troughs and toxicity, and MA recipients
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recovery (p¼0.005). In a competing risk 2-week landmark
analysis, there were no differences grade II-IV aGVHD
incidences (61% vs 57%, p¼0.52) according to troughs.
However, patients with a lowMPA trough early post-CBT had
nearly triple the incidence of grade III-IV aGVHD (27.8% vs
9.5%, p¼0.06, Figure).
Conclusions: Higher total MPA troughs are safe and may
protect against severe aGVHD. The platelet beneﬁt could be
explained by the lower severe aGVHD incidence. Prospective
investigation of MPA troughs, and ultimately intervention
based on drug monitoring in CBT recipients is warranted.48
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In spite of intense efforts, control of graft versus host disease
(GvHD) remains incomplete and novel therapeutic ap-
proaches are required. Cdk2 has a central role in cell cycle
re-entry of mature T lymphocytes and inhibition of Cdk2 is
mandatory for induction of T cell anergy in vitro and toler-
ance in vivo. To determine the effects of Cdk2 inhibition on
GvHD, we used the B6D2F1 mouse model of allogeneic BMT
and two different Cdk2 inhibitors (Cdk2i), CYC202 and
CYC205. Lethally irradiated B6D2F1(Kd) recipients were
infused with bone marrow from C57BL/6(Kb) donors with
(BMT) or without splenocytes andwere subsequently treated
with each Cdk2i for three weeks. Treatment was adminis-
tered daily during week 1, every other day on week 2, and
twice a week on week 3 followed by assessment of GvHD
during a 70-day period. BMT recipients treated with Cdk2i
displayed a transient weight loss and subsequently regained
weight to levels comparable to controls. Treated BMT re-
cipients also displayed delayed GvHD mortality (p¼0.0054).
Treg have a central role in mediating protection from GvHD.
To examinewhether Cdk2i induced Treg, we used GFP- T cells
from Foxp3.GFP-KI mice as a source of T cells. Assessment of
peripheral blood lymphocytes, splenocytes, lymph nodes
and intestinal lymphoid cells (ILC) in treated and control
BMT recipients revealed no differences in CD4+GFP+ Treg. In
contrast, CD8+GFP+ Treg were increased in the treated group,
predominantly in ILC, which displayed a 5-fold increase of
CD8+ Treg (p¼0.05). To investigate the mechanisms via
which Cdk2i had a selective effect on CD8+ Treg, we isolated
CD4+GFP- and CD8+GFP- T cells from Foxp3.GFP-KI mice and
subjected them to in vitro Treg polarization. Cdk2i had
almost no effect on CD4+GFP+ cells but induced a 2-4 fold
increase of CD8+GFP+ cells. Culture of CD8+GFP- cells with
stable concentrations of Cdk2i and decreasing concentra-
tions of TGF-b revealed that Cdk2i induced CD8+ Treg
differentiation in the presence of TGF-b concentrations that
failed to induce CD8+ Treg cells when used alone. Expression
of FOX family genes is regulated by transcriptional and
epigenetic mechanisms. A critical epigenetic regulator of FOX
transcription factors in cancer cells is the Polycomb group
(PcG) protein, enhancer of zeste homologue 2 (EZH2), which
promotes histone H3 lysine 27 trimethylation (H3K27me3)
and induces epigenetic gene silencing. Cdk1 and Cdk2 phos-
phorylate EZH2 at Thr350 in an evolutionarily conserved
motif. Phosphorylation of Thr350 is important for EZH2
recruitment and maintenance of H3K27me3 levels at EZH2-target loci. Uponpolarizing CD8+ Tcell culture, EZH2 displayed
robust phosphorylation on Thr350, which was blocked by
Cdk2i. This event temporally coincidedwith a 44-fold increase
in Foxp3 mRNA expression compared to control T cells. These
results reveal an unexpected mechanism via which Cdk2 in-
hibitors induce CD8+ Treg and protection from GvHD.49
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Factors regulating damage and regeneration of the intestinal
epithelium after allogeneic BMT are poorly understood. We
have previously shown that IL-22 produced by recipient-
derived innate lymphoid cells (ILCs) provides a critical signal
for epithelial recovery following experimental BMT. How-
ever, intestinal IL-22 levels are reduced in GVHD due to the
elimination of radioresistant host ILCs. We therefore sought
to determine if IL-22 administration post-BMT could negate
the effect of ILC elimination and reduce GVHD pathology. We
utilized a clinically modeled LP into C57BL/6 (B6) minor
antigen mismatched model with T cell-depleted marrow and
puriﬁed T cells transplanted into lethally irradiated mice.
We found that daily administration of rIL-22 (4ug IP starting
day+7) led todecreasedGVHDpathology in recipient small and
large intestine three weeks post-BMT (p<0.001). Further
assessmentof the intestinal pathology indicated that recipients
of rIL-22 had decreased intestinal crypt apoptosis in both small
and large intestine (p<0.01)withnodifference in intestinal and
splenic lymphocytes or inﬂammatory cytokine levels.
To assess the effects of IL-22 administration on the intestinal
stem cell (ISC) compartment, we performed LP into B6 allo-
HCT using Lgr5-LacZ ISC reporter mice. Recipients treated
with rIL-22 demonstrated increased numbers of Lgr5+ ISC
three weeks post-HCT during active GVHD with no immu-
nosuppression (p<0.05). Furthermore, we found increased
ISC Ki-67 expression in Lgr5-GFP reporter mice with GVHD
after IL-22 treatment, indicating increased ISC proliferation
in response to IL-22.
In addition to Lgr5+ cells, it has been reported that BMI-1+
crypt cells may possess ISC activity after crypt damage. Crypt
cells from BMI-1-GFP reporter mice were indeed found to be
IL-22R+ at baseline (7-10% IL-22R surface expression).
However, BMI-1 mRNA expression in small intestine of mice
with GVHD was not affected by IL-22 administration,
suggesting that the effect of IL-22 administration in vivo was
not due to stimulation of BMI-1+ cells. Additionally, there
was no difference in Wnt3 or EGF expression, arguing that
improved ISC survival after IL-22 administrationwas not due
to improvement in ISC niche function. In contrast, IL-22
treatment demonstrated increased Reg3g (p<0.001) and
Reg3b (p<0.01) expression, suggesting a potential antimi-
crobial beneﬁt of IL-22 administration.
In summary, we found that IL-22 administration could
reduce intestinal pathology and improve ISC recovery in
GVHD. This appeared to be due to direct stimulation of Lgr5+
ISCs, and not due to improved support of the ISC niche. These
